



## Clinical Developments of the Tumor Suppressor p53

Guest Editor:

### Dr. Naoise C. Synnott

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA

Deadline for manuscript submissions:

**closed (31 May 2023)**

### Message from the Guest Editor

This Special Issue, "Clinical Developments of the Tumor Suppressor p53", will mainly focus on the most promising advancements in clinical research on how p53 and its mutations impact patients in the clinic and on the novel drugs currently advancing to clinical trials to treat this once "undruggable" target.

*TP53* (p53) is the most frequently mutated gene in cancer, being altered in approximately 50% of human malignancies. In most, if not all, cancers lacking mutations, wild-type (WT) p53 is inactivated through interaction with cellular (MDM2/MDM4) or viral proteins, leading to its degradation. Because of its near universal alteration in cancer, p53 is an attractive target for the development of new targeted therapies for this disease.

We invite authors to submit original research and review articles that focus on the biological functions and therapeutic potential of the p53 pathway. Potential topics include, but are not limited to, the following:

- P53 targeted therapies;
- MDM2/4 targeted therapies;
- Role of p53 in drug resistance;
- Role of p53 in secondary cancers;
- Therapeutic options for Li–Fraumeni syndrome.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI